Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06643221 · ClinicalTrials.gov registry record · Early Phase 1
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
A Early Phase 1 study of Lymphoma and Leukemia, sponsored by University of Arizona.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06643221 is a Early Phase 1 study of Lymphoma and Leukemia that is actively recruiting participants, run by University of Arizona. The registered enrollment target is 100 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06643221, a Early Phase 1 study of Lymphoma and Leukemia, is actively recruiting participants, sponsored by University of Arizona.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to improve the treatment of blood cancer by using exercise to collect healthier immune cells from donors. Allogeneic adoptive cell therapy is a treatment where immune cells from a healthy donor are given to a cancer patient, usually to help prevent or treat cancer relapse after a stem cell transplant. These donor cells can either be directly infused into the patient or grown in a lab to create more specialized immune cells that target and kill cancer. While this therapy has been helpful for many patients, there is a need to make it more effective for a larger group and reduce side effects like graft-versus-host disease (GvHD), where the donor's immune cells attack the patient's healthy tissue. This Early Phase 1 trial will test whether exercise can help produce better immune cells from donors. The investigators will recruit healthy participants for three study groups: 1. Exercise Group: Participants will complete a 20-minute cycling exercise session. The investigators will collect blood samples before, during, and after exercise to study the number and quality of immune cells. The investigators will also use the collected cells to create immune therapies and test their ability to kill cancer cells in the lab and control cancer growth in mice. 2. Exercise and Beta Blocker Group: In this group, participants will complete up to five cycling sessions, with at least a week between each session. Before each session, participants will take either a placebo or a drug (beta blocker) that blocks stress hormones like adrenaline. The investigators will collect blood samples before and during exercise to see how blocking these hormones changes the effect of exercise on immune cells. 3. Isoproterenol Group: Participants in this group will receive a 20-minute infusion of isoproterenol, a drug that mimics the effects of adrenaline. The investigators will collect blood samples before, during, and after the infusion to see if the drug causes similar immune changes t
Conditions Studied
Interventions
- DRUG Placebo
- BEHAVIORAL Exercise
- DRUG Isoproterenol
- DRUG Bisoprolol Fumarate Tablet 10 mg
- DRUG Nadolol (1 x 80 mg) Tablets (Invamed, Inc)
Study Locations (1)
Arizona
- The University of Arizona - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-01-24 |
| Est. Completion | 2028-12-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06643221
The ClinicalTrials.gov registry entry for NCT06643221 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (79% lower). The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT06643221 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT06643221 about?
NCT06643221 is a clinical study titled "Exercise as an Immune Adjuvant for Allogeneic Cell Therapies". This study aims to improve the treatment of blood cancer by using exercise to collect healthier immune cells from donors. Allogeneic adoptive cell therapy is a treatment where immune cells from a healthy donor are given to a cancer patient, usually to help prevent or treat cancer relapse after a ste...
What is the current status of trial NCT06643221?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 100 participants. The study started on 2018-01-24. Estimated completion is 2028-12-30.
What conditions does trial NCT06643221 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, CAR T-Cell Therapy, Cell Therapy, Hematopoetic Stem Cell Transplantation.
What interventions are being tested in trial NCT06643221?
The interventions under investigation include: Placebo (DRUG), Exercise (BEHAVIORAL), Isoproterenol (DRUG), Bisoprolol Fumarate Tablet 10 mg (DRUG), Nadolol (1 x 80 mg) Tablets (Invamed, Inc) (DRUG).
Who is sponsoring clinical trial NCT06643221?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06643221 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
RECRUITING · Early Phase 1
-
Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma
RECRUITING · Early Phase 1
-
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RECRUITING · Early Phase 1
-
Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel
ACTIVE NOT RECRUITING · Early Phase 1
-
A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
ACTIVE NOT RECRUITING · Early Phase 1
-
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
COMPLETED · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.